Evotec SE (EVT.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Mario Polywka DPHIL, Ph.D. | Interim CEO, Member of the Management Board & Member of the Supervisory Board | -- | -- | 1963 |
| Dr. Werner Lanthaler M.B.A., MPA, Ph.D. | Member of Management Board | 1.32M | -- | 1968 |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer & Member of Management Board | 804k | -- | 1964 |
| Dr. Craig Johnstone Ph.D. | COO & Member of Management Board | 712k | -- | 1970 |
| Dr. Matthias Evers Ph.D. | Chief Business Officer & Member of Management Board | 636k | -- | 1973 |
| Ms. Laetitia Rouxel | CFO & Member of Management Board | -- | -- | 1974 |
| Ms. Anja Bosler | Principal Accounting Officer and Senior Vice President of Group Accounting | -- | -- | -- |
| Mr. Volker Braun | Executive VP and Head of Global Investor Relations & ESG | -- | -- | -- |
| Dr. Christian Dargel | EVP Global Head of Legal & Compliance | -- | -- | -- |
| Gabriele Hansen | Senior VP & Head of Global Corporate Communications & Marketing | -- | -- | -- |
Evotec SE
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 5,086
Description
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Corporate Governance
Recent Events
Recent Events Information Not Available